Key Highlights
- These 10 stocks could mint the next wave of millionaires › On November 13, Oregon-based Stonepine Capital Management reported in its latest SEC filing that it fully exited its position in ANI Pharmaceuticals (NASDAQ:ANIP), reflecting a $2.52 million net decrease.
- What Happened According to a regulatory filing with the Securities and Exchange Commission dated November 13, Stonepine Capital Management sold its entire position of 38,597 shares in ANI Pharmaceuticals (NASDAQ:ANIP).
- The value of the transaction, based on average quarterly prices, was $2.52 million.
- What Else to Know Top holdings after the filing: NASDAQ:VSTM: $23.58 million (19.17% of AUM) NASDAQ:ADMA: $10.83 million (8.81% of AUM) NASDAQ:EOLS: $9.43 million (7.67% of AUM) NASDAQ:ZVRA: $7.70 million (6.26% of AUM) NASDAQ:NKTR: $4.84 million (3.93% of AUM) As of Friday, shares of ANI Pharmaceuticals were priced at $82.41, up 49% over the past year and well outperforming the S&P 500, which is up about 15% in the same period.
- Company Overview Metric Value Market Capitalization $1.85 billion Revenue (TTM) $826.89 million Net Income (TTM) $40.57 million Price (as of Friday) $82.41 Company Snapshot ANI Pharmaceuticals develops, manufactures, and markets branded and generic prescription pharmaceuticals, with a focus on controlled substances, oncology products, hormones, steroids, injectables, and oral solid dose formulations.
